ライフサイエンスコーパス: point-of-care

1 ve detection of a variety of diseases at the point of care.

2 ant laboratory-based, real-time NAATs to the point of care.

3 tumor-derived exosomes to a medical use at a point of care.

4 roperly for appropriate treatment during the point of care.

5 ent-free, visual SARS-CoV-2 detection at the point of care.

6 f infections and inconvenient for use at the point of care.

7 ting in delayed therapeutic decisions at the point of care.

8 in research laboratories, rather than at the point of care.

9 city and potential for implementation at the point of care.

10 affordable smartphone-based detection at the point of care.

11 or rapid, large-scale data generation at the point of care.

12 d detection should facilitate testing at the point of care.

13 lingual microcirculation measurements at the point-of-care.

14 detection of such pathogens at the patient's point-of-care.

15 tandard technologies suitable for use at the point-of-care.

16 ess to identify high-risk IH patients at the point-of-care.

17 CA-based molecular diagnostics closer to the point-of-care.

18 ting in resource limited settings and at the point-of-care.

19 chemistry analyzers that are not amenable to point-of-care analysis or home monitoring and cannot pro

20 detection tests could be most useful at the point of care and add to the currently available serolog

21 ls the current state of data obtained at the point of care and describes the changes necessary to use

22 e intraclass correlation coefficient between point of care and expert optic nerve sheath diameter aft

23 HIV infection compared to RT but LBT is not point of care and may result in fewer diagnoses due to l

24 s and are best diagnosed by a combination of point-of-care and conventional coagulation and platelet

25 stock diseases for development of diagnostic point-of-care and field surveillance.

26 dentification of bacterial infections at the point-of-care and their usefulness in providing a hugely

27 Following the need for point-of-care and wearable sensors, designs have transit

28 rapid detection of patients, possibly at the point of care, and for optimized prevention and treatmen

29 e detection of this ubiquitous fungus at the point-of-care, and could help to improve clinical decisi

30 ence, particularly for those in the field of point-of-care, and it is intended to provide the know-ho

31 e with COVID-19 and risk factors, received a point-of-care antibody test, and, if agreed, donated a b

32 Rapid, point-of-care antigen and molecular-based tests for diag

33 success of capillary recruitment, improving point-of-care application of microcirculatory-targeted r

34 g CRISPR sensing in miniaturized sensors for point-of-care applications.

35 ry, bringing the latter a step closer toward point-of-care applications.

36 in urine, suitable for field deployment and point-of-care applications.

37 mmunoassays suitable for both laboratory and point-of-care applications.

38 expensive and portable electronic reader for point-of-care applications.

39 eir increased exploration in bioanalysis and point-of-care applications.

40 le, LA-REIMS offers unique opportunities for point-of-care applications.

41 e single-tube assay is beneficial for future point-of-care applications.

42 y and optic nerve ultrasound measured at the point-of-care as well as remotely by an expert blinded t

43 ntial to provide a rapid, sensitive, one-pot point-of-care assay for SARS-CoV-2.

44 in phenotype identification, currently lack point-of-care assays and represent a barrier to the clin

45 Point-of-care assays for optical detection of biomolecul

46 enhance antimicrobial stewardship, multiple point-of-care assays have been developed.

47 p, opening the way to simple and inexpensive point-of-care assays.

48 al-time measurements of body composition and point-of-care assessment of clinical condition.

49 s and sensitivity for applications targeting point-of-care bio-sensing.

50 opy for application in clinical settings for point-of-care biochemical analysis is discussed.

51 e of our technology for the realization of a point-of-care biosensing platform for the detection of m

52 es, and pathways to deployment of a complete point-of-care biosensing system in a clinical setting.

53 we discuss the feasibility of an integrated point-of-care biosensor system with mobile health for wa

54 it will be possible to design and develop a point-of-care biosensor with multiplexing capabilities f

55 (LFA) have made them some of the most common point of care biosensors in a variety of fields.

56 ill be used both at the bedside as well as a point-of-care blood perfusion imaging device to visualiz

57 diagnostic test to meet the requirements for point-of-care cell-free tumor DNA (ctDNA) and microRNA (

58 Our approach has scope for point-of-care clinical application to aid in the diagnos

59 of asymptomatic carriers as well as a rapid point-of-care clinical diagnostic for nonfalciparum mala

60 patibility with development into a potential point-of-care clinical tool.

61 Finally, we discuss the challenges of point-of-care CRISPR sensing and describe future researc

62 We measured point-of-care CSF lactate at the bedside of 319 HIV-infe

63 Baseline point-of-care CSF lactate levels may be utilized as a pr

64 More research is needed to facilitate point-of-care decision support and examine BREASTChoice'

65 ombined with LAMP-AuNP/STR present effective point-of-care detection and facilitate appropriate contr

66 ions of paper-based bioassays especially for point-of-care detection in resource-poor settings.

67 ds great potential for future development of point-of-care detection kits for cancer diagnosis in a c

68 The automated, rapid, and noninvasive point-of-care detection of chocolate bloom has been an e

69 We found a low sensitivity of BN for point-of-care detection of RSV infection.

70 forms make them a strong candidate for rapid point-of-care detection of SARS-CoV-2 infection by targe

71 osensing methods especially for in-field and point-of-care detection of SARS-CoV-2.

72 arious pancreatic ailments and an affordable point-of-care detection of this biomarker can benefit mi

73 sing principle is of increasing interest for point-of-care detection, but has rarely been applied in

74 to-use, and fast hematological analyzer as a point-of-care device and for low-resource settings.

75 The developed point-of-care device encompasses a disposable sensor car

76 the approach as its potential utilization as point-of-care device for clinical analysis but drawing n

77 meets the clinical requirements as a future point-of-care device for clinical analysis.

78 We report an electrochemical point-of-care device for the fast, simple and quantitati

79 in, we demonstrate a first-of-its-kind novel point-of-care device that uses a unique approach by dire

80 Rapid Electro-Analytical Device (READ) is a point-of-care device that uses impedance change between

81 It envisioned the potential of a point-of-care device with full-analysis for practical di

82 capability of paper-based origami sensors as point of care devices to customize the drug administrati

83 but also offers a great potential for future point-of-care devices and personalized medicine.

84 In this Review, we appraise innovative point-of-care devices that enable the early diagnosis of

85 Accurate and scalable point-of-care devices would increase screening, diagnosi

86 nd flexible, and has demonstrated utility in point-of-care devices.

87 rization of an example, the first autonomous point-of-care diabetic retinopathy examination de novo a

88 Biomarkers have the potential to provide point of care diagnosis, identify high-risk patients, an

89 he proposed assay may become a prototype for point-of-care diagnosis of drug resistant bacteria with

90 tamer-based FET biosensor has potential as a point-of-care diagnosis of H5N1 AIVs in clinical samples

91 Current technologies for the point-of-care diagnosis of traumatic brain injury (TBI)

92 highly contagious disease for which prompt, point-of-care diagnosis remains an unmet clinical need.

93 As effective point-of-care diagnosis tools, simple, low-cost and rapi

94 cted to become a promising tool for clinical point-of-care diagnosis towards precision medicine.

95 ends of in-field and real-time detection for point-of-care diagnosis, food safety and environmental m

96 r combined pre-/post-capillary PH now guides point-of-care diagnosis, risk stratification, and treatm

97 cycle of NAATs, our platform may find use in point-of-care diagnosis.

98 However, the development of point-of-care diagnostic assays based on this binding ha

99 Point-of-care diagnostic assays often involve multistep

100 e central nervous system lacking an adequate point-of-care diagnostic test.

101 Point-of-care diagnostic tests for detecting SARS-CoV-2

102 roving the capabilities of current low-cost, point-of-care diagnostic tests.

103 idic technologies are frequently employed as point-of-care diagnostic tools for improving time-to-dia

104 or high-performance, rapid, and portable (or point-of-care) diagnostic sensors in applications spanni

105 Sensitive point-of-care diagnostics are also lacking for nonfalcip

106 programs and a promising platform for rapid point-of-care diagnostics for citrus farmers and small n

107 is an urgent need for low-cost but reliable point-of-care diagnostics for early screening of infecti

108 r-based DNA biosensors are powerful tools in point-of-care diagnostics since they are affordable, por

109 -based biosensors merge as powerful tools in point-of-care diagnostics since they are cheap, portable

110 In particular, point-of-care diagnostics that are able to reduce and/or

111 can find potential applications ranging from point-of-care diagnostics to education, as well as helpi

112 6%), establish new performance standards for point-of-care diagnostics with samples of human serum.

113 pecific NAT platform with great potential in point-of-care diagnostics.

114 clinical laboratories, blood banks, and for point-of-care diagnostics.

115 evant key-performance indicators required in point-of-care diagnostics.

116 )integrated on a chip hold great promise for point-of-care diagnostics.

117 ysis of human biofluids, essential for rapid point-of-care diagnostics.

118 to deployment with microfluidic devices for point-of-care diagnostics.

119 mpared the diagnostic performance of a novel point-of-care duplex ultrasound test (podiatry ankle dup

120 r drug administration during cardiac arrest, point-of-care echocardiography for intra-arrest prognost

121 f the drawbacks that impede their definitive point-of-care establishment.

122 Collaborative (point-of-care) evaluation models between health care and

123 Point-of-care fluorescent detection of skin cancer had a

124 ratory-based assays into a user-friendly and point-of-care format with a sensitivity and specificity

125 tients with retrospective urine testing, the point-of-care Fujifilm SILVAMP TB LAM (FujiLAM) could ha

126 scale-up, this technology could be used for point-of-care gas phase NO generation as an alternative

127 were randomly assigned to prospective rapid point-of-care genotyping of CYP2C19 major alleles (*2, *

128 s of tuberculosis symptoms, body-mass index, point-of-care haemoglobin concentrations, and urine lipo

129 PGMs for the detection of any analyte at the point-of-care have been one focus of biosensor research

130 immense consequence towards developing novel point-of-care hematological analyzers for resource-const

131 There were no adverse events related to point-of-care HIV viral load testing or task shifting.

132 he aim of our study was to determine whether point-of-care HIV viral load testing with task shifting

133 g oligonucleotide-based molecular detection, Point-of-Care immunodiagnostics, radiographical analysis

134 d DILI screening fails to be executed at the point-of-care in LMICs.

135 assa Antigen Rapid Test (Pan-Lassa RDT) is a point-of-care, in vitro diagnostic test that utilizes a

136 nswer (DiaSorin Simplexa, GenMark ePlex) and point-of-care instruments (Abbott ID NOW).

137 , by BioMedomics SARS-CoV-2 combined IgM-IgG point-of-care lateral flow immunoassay.

138 tis C burden and reflex testing outperformed point-of-care linkage indicators.

139 Point-of-care lung ultrasound (LUS) is a promising pragm

140 The major growth in point-of-care malaria diagnosis over the past decade has

141 aneously quantifying cell concentration in a point-of-care manner.

142 We aimed to develop a rapid, inexpensive, point-of-care means of identifying patients with atrial

143 ent biosensing strategies that allow for the point-of-care measurement of miRNAs.

144 Xpert Xpress Flu (Xpert; Cepheid) are rapid, point-of-care molecular assays for Flu virus detection.

145 potential for development of next-generation point-of-care molecular diagnostics.

146 ly, confirming the practical application for point of care monitoring.

147 erization and enable continuous non-invasive point-of-care monitoring of CVP, without restricting pat

148 However, they are unsuitable for point-of-care multistep reactions because they sacrifice

149 of diseases and decentralising healthcare to point-of-care needs.

150 mprove the accessibility of brain MRI at the point of care, particularly for critically ill patients.

151 opment of simple, sensitive smartphone-based point-of-care pathogen diagnostics in resource-limited s

152 n of RISK6 into rapid, capillary blood-based point-of-care PCR devices for prospective assessment in

153 ighlight the need for sensitive and accurate point-of-care platforms for quantification of disease bi

154 oa increases amenability to integration into point-of-care platforms.

155 bricated Coulter counters are attractive for point of care (POC) applications since they are label fr

156 ction of a broad range of target analytes in point-of-care (POC) and continuous applications.

157 nsuming, complex, and cannot be performed at point-of-care (POC) and home settings.

158 forms for biosensing in various clinical and point-of-care (POC) applications.

159 to design a specific biosensor for requested point-of-care (POC) applications.

160 g a new dual aptamer assay was developed for point-of-care (POC) applications; magnetic beads coated

161 t measure multiple cardiac biomarkers at the point-of-care (POC) are needed to improve clinical outco

162 However, most current point-of-care (POC) assays are limited in sensitivity.

163 There is an unmet need in clinical point-of-care (POC) cancer diagnostics for early state d

164 ctrochemical test strip for the quantitative point-of-care (POC) determination of acetaminophen (para

165 nd ease of use, and are often considered for point-of-care (POC) development.

166 ticle introduces a gel-based separation-free point-of-care (POC) device for whole blood glucose color

167 A point-of-care (POC) device to enable de-centralized diag

168 king it a promising candidate for its use in point-of-care (POC) devices.

169 For in-situ disease markers detection, point-of-care (POC) diagnosis has great advantages in sp

170 However, early, accurate, and specific point-of-care (POC) diagnosis of ZIKV is very difficult

171 malaria from endemic regions, and sensitive point-of-care (POC) diagnostic tests are required to sup

172 ign and develop new biosensing platforms for point-of-care (POC) diagnostics to manage the coronaviru

173 oncentrated on engineering paper devices for point-of-care (POC) diagnostics, which could be integrat

174 , cost-effective, portable and user-friendly point-of-care (POC) disease diagnostic platform technolo

175 Point-of-care (POC) immunodiagnostic tests play a crucia

176 inical samples using a simple and accessible point-of-care (POC) instrument.

177 Hence, there is an urgent need for Point-of-care (PoC) methods, which can quantify micropro

178 disease and protect human populations, rapid point-of-care (POC) molecular diagnosis of human and pla

179 Several point-of-care (POC) molecular tests have received emerge

180 We report a paper-based sensor system for a point-of-care (POC) nucleic acid amplification test that

181 We present a rapid and quantitative point-of-care (PoC) system based on a smartphone applica

182 l CRISPR-Cas assay with a fluorescence-based point-of-care (POC) system for rapid and accurate virus

183 oss-sectional study aims to investigate if a point-of-care (PoC) test of active matrix metalloprotein

184 Point-of-care (POC) tested 4293 individuals (10% [427] a

185 Point-of-care (POC) testing for ART monitoring might all

186 ommunicable diseases (NCDs) urgently needs a point-of-care (PoC) testing infrastructure.

187 Early disease detection through point-of-care (POC) testing is vital for quickly treatin

188 ices (muPADs) has revolutionized the area of point-of-care (POC) testing towards highly sensitive and

189 Point-of-care (POC) testing with rapid turnaround times

190 nd convenient biosensors, otherwise known as point-of-care (POC) testing.

191 imed to assess the clinical performance of a point-of-care (POC)-hs-cTnI assay in patients with suspe

192 Many recently released point-of-care (PoCT) serological assays have been distri

193 nd of graft rejection, and should facilitate point-of-care post-transplantation monitoring.

194 urface markers on cancer cells can allow for point-of-care prediction of patient response to various

195 makes the sp-SlipChip very appealing for the point-of-care quantitative analysis of viral load.

196 D PARTICIPANTS: Multicenter, noninferiority, point-of-care randomized clinical trial including adults

197 y reviewing evidence-based summary sources ("point-of-care resource test"), not merely requesting log

198 Point-of-care results were available faster than convent

199 rtificial intelligence-assisted nonmydriatic point-of-care screening administered during primary care

200 has the potential to enable rapid, low-cost, point-of-care screening for SARS-CoV-2.

201 table and multiplex paper based platform for point-of-care screening of chicken carcasses for Campylo

202 these infectious agents necessitates rapid, point-of-care sensors for their detection, identificatio

203 r this assay approach to be made useful in a point of care setting, though this half-strip LFA may se

204 of blood allowing initial pre-screening in a point of care setting.

205 ity to develop rapid diagnostic tests at the point-of-care setting.

206 he quantitative analysis of tear analytes in point-of-care settings can enable early diagnosis of ocu

207 ients and assist clinical decision making at point-of-care settings.

208 ification assay for viral load monitoring at point-of-care settings.

209 in the testing of whole blood samples in the point-of-care settings.

210 the detection of analytes in the field or at point-of-care situations.

211 e conducted a head-to-head evaluation of ten point-of-care-style lateral flow assays (LFAs) and two l

212 RNA markers combined with emerging molecular point-of-care systems has the potential to greatly accel

213 ategy will be of especially high utility for point-of-care systems owing to the programmability, modu

214 acid amplification test platforms, including point-of-care systems that facilitate active case-findin

215 n of electrochemical biosensors to practical point-of-care systems, such as rapid readout, simple bio

216 make it promising for future adaptation into point-of-care systems.

217 However, point-of-care technologies and serologic immunoassays ar

218 We envision that once emerging point-of-care technologies can reliably capture real-tim

219 For several decades, point-of-care technology (POCT) has proven its potential

220 se progression, which makes development of a point of care test (POCT) platform extremely desirable f

221 Rapid point of care test for detecting urogenital Chlamydia tr

222 Ideally, an initial indicative point of care test would provide guidance to seek testin

223 at these five centres, using an ELISA-based point-of care test (HemoTypeSC).

224 Implementing a novel point-of-care test (POCT) for influenza in the emergency

225 In this work, we developed a handheld point-of-care test (POCT) to measure PT using electrical

226 assay (FIA), a rapid antigen-based influenza point-of-care test (POCT), combined with Virena software

227 test alongside a different immunoassay-based point-of-care test (SickleSCAN) and the gold standard te

228 gave consent, were tested by the HemoTypeSC point-of-care test alongside a different immunoassay-bas

229 oprevalence was 5.0% (95% CI 4.7-5.4) by the point-of-care test and 4.6% (4.3-5.0) by immunoassay, wi

230 rticipants who were seropositive by both the point-of-care test and immunoassay reported a previous P

231 disease screening programme using innovative point-of-care test devices into existing immunisation pr

232 ore Technology has the potential to become a point-of-care test for infectious disease in public heal

233 oad Fingerstick assay (Xpert HCV VL FS) is a point-of-care test quantifying HCV RNA in <1 hour, enabl

234 children younger than 10 years (<3.1% by the point-of-care test).

235 sable stand-alone chip, can be operated as a point-of-care test, but also it might represent a promis

236 trating the feasibility of an intraoperative point-of-care test, rotational thromboelastometry, to sc

237 SARS-CoV-2 was assessed using a lateral flow point-of-care test, the WONDFO SARS-CoV-2 Antibody Test

238 ry health-care centres using the ELISA-based point-of-care test.

239 o demonstrate accuracy when implemented as a point-of-care test.

240 Both technologies elegantly meet the point of care testing or bed side device requirements su

241 ial applications in clinical diagnostics and point of care testing.

242 Point-of-care testing (POCT) assays for chlamydia are be

243 A miniature internet of things (IoT)-based point-of-care testing (PoCT) fluorescence reader, able t

244 r, AEC-based universal sensors applicable to point-of-care testing (POCT) have not yet been developed

245 d for rapid analysis, reliable detection and point-of-care testing (POCT).

246 Point-of-care testing can simplify treatment and improve

247 However, a calibration free point-of-care testing device is required for fast screen

248 on and may affect the diagnostic accuracy of point-of-care testing for albuminuria.

249 This review describes current point-of-care testing for group A streptococcal pharyngi

250 s (e.g., dengue fever and leptospirosis) and point-of-care testing for the virus is still uncommon.

251 it will have great potential for multiplexed point-of-care testing in resource-limited regions.

252 nologies enabling the widespread adoption of Point-of-Care testing in routine clinical practice.

253 Our study initially employed point-of-care testing methods but this resulted in a hig

254 CL-based biosensors appear more suitable for point-of-care testing of clinical biomarkers, where dete

255 ey are also well placed to be repurposed for point-of-care testing of other analytes as they are inex

256 ed settings thus, improving accessibility to point-of-care testing services.

257 d-deployable paper-based device as a general point-of-care testing tool for protein biomarker detecti

258 paper-based point-of-care testing, and 2.

259 abilities, which include miniaturization for point-of-care testing, direct complex mixture analysis v

260 choosing a method for group A streptococcal point-of-care testing, implementation of molecular group

261 was introduced to combine with the ALISA for point-of-care testing, indicating the high feasibility i

262 omatographic immunoassay used for SARS-CoV-2 point-of-care testing, was evaluated using nasal specime

263 many different read-out methods for on-site point-of-care testing.

264 portable miniaturized fluid handling such as point-of-care testing.

265 remote monitoring, video communication, and point-of-care testing.

266 method was adopted, enabling a rapid simple point-of-care testing.

267 is and monitoring for prognostic use towards point-of-care testing.

268 country have been incorporating CLIA-waived point-of-care tests (POCT) into disease screening and ma

269 in (CRP) and procalcitonin (PCT) measured by Point-of-Care tests (PoCT) to diagnose UTI in this setti

270 Many recent studies reported coronavirus point-of-care tests (POCTs) based on isothermal amplific

271 Point-of-care tests (thrombelastometry/platelet aggregom

272 We concentrate on the point-of-care tests and discuss the basis for new serolo

273 The head-to-head comparison between the two point-of-care tests and HPLC showed concordance between

274 exed technologies (including biomarker-based point-of-care tests and molecular platform technologies)

275 Point-of-care tests are reliable and accurate in newborn

276 le diagnostic procedures are available, with point-of-care tests becoming increasingly important wher

277 Point-of-care tests often rely on integrated plasma filt

278 Cellex's qSARS-CoV-2 IgG/IgM Rapid Test, and point-of-care tests such as Abbott's ID NOW COVID-19 Tes

279 Point-of-care tests such as SAMBA should enable rapid pa

280 formance of our approach could enable better point-of-care tests.

281 nd the development of emerging biosensors as point-of-care tests.

282 infection management in women by introducing point-of-care tests.

283 ing patients for a wide range of diseases at point-of-care, thereby relieving the pressure on overstr

284 pid detection of these emerging pathogens at point-of-care to provide the appropriate treatment in th

285 Electronic noses (eNoses) are emerging point-of-care tools that may help in the subphenotyping

286 A prospective evaluation of point-of-care ultrasonographic diagnosis of diverticulit

287 ent of optic nerve sheath diameter (ONSD) by point-of-care ultrasound may aid in the identification a

288 Although doctors commonly attend point-of-care ultrasound short-courses for introductory

289 est) is a World Health Organization-endorsed point-of-care urine test designed to detect active TB di

290 ntrations can inform interpretation of novel point-of-care urine-based TFV assays to assess recent TD

291 nucleic acid amplification technologies for point-of-care use are being developed to improve perform

292 expensive instruments, thus not suitable for point-of-care use.

293 Rapid point-of-care viral antigen detection methods have been

294 number allocation sequence to receive either point-of-care viral load testing at enrolment and after

295 Point-of-care viral load testing combined with task shif

296 icularly true for clinical situations at the point-of-care where access to state-of-the-art diagnosti

297 iet quality be assessed and discussed at the point of care with clinicians and other members of the h

298 -access, integrated devices available at the point of care with scalable capacities will facilitate t

299 is shown that the BEM can be prepared at the point-of-care within 26 min using fresh blood, it can be

300 d low-cost magnetic-resonance devices at the point of care would alleviate the accessibility and cost